NEJM, Eric Topol, Ethan Weiss, and Martha Gulati highlight Ez-PAVE: targeting LDL below 55 mg/dL reduced 3-year cardiovascular events versus targeting below 70 mg/dL, reinforcing “lower is better” in secondary prevention.
targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events
Validation of aggressive LDL lowering to reduce major adverse cardiovascular events
Another win for the lower is better crowd…
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo
aggressive lowering of LDL ⤵️ MACE
targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter.
EZ-PAVE compares LDL-C targets of <55 mg/dL vs <70 mg/dL
“targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter.”
“Validation of aggressive LDL lowering to reduce major adverse cardiovascular events, a randomized trial targeting LDL < 55 mg/dl.”
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare